United States - English - NLM (National Library of Medicine)

redpharm drug inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride 500 mg - ciprofloxacin tablets usp are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter diversus , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or enterococcus faecalis . acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus . chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or

United States - English - NLM (National Library of Medicine)

medvantx, inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 500 mg - ciprofloxacin tablets usp are indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli , klebsiella pneumoniae , enterobactercloacae , serratia marcescens , proteus mirabilis , providencia rettgeri, morganella morganii , citrobacter koseri(diversus) , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcusepidermidis , staphylococcus saprophyticus , or vancomycin-susceptible enterococcus faecalis . acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus . chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemo

United States - English - NLM (National Library of Medicine)

apothecary shop wholesale inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride 500 mg - ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, serratia marcescens, proteus mirabilis, providencia rettgeri, morganella morganii, citrobacter diversus, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or enterococcus faecalis. acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus. chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or penicillin-suscept

United States - English - NLM (National Library of Medicine)

testpak holding company - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride 500 mg - ciprofloxacin tablets, usp are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, serratia marcescens, proteus mirabilis, providencia rettgeri, morganella morganii, citrobacter diversus, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or enterococcus faecalis. acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus. chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or penicillin-sus

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; macrogol 4000; hypromellose; maize starch; sodium starch glycollate; magnesium stearate; titanium dioxide; purified talc - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty 500 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; purified talc; hypromellose; macrogol 4000; titanium dioxide; maize starch; sodium starch glycollate; magnesium stearate - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - ciprofloxacin hydrochloride (equivalent: ciprofloxacin, qty 250 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; maize starch; purified talc; titanium dioxide; sodium starch glycollate; microcrystalline cellulose; magnesium stearate; hypromellose; macrogol 4000 - ciprofloxacin is indicated for treatment of infections caused by susceptible organisms in the conditions listed below: urinary tract infections; gonorrhoeal urethritis and cervicitis; gastroenteritis; bronchial infections; skin and skin structure infections; bone and joint infections; chronic bacterial prostatitis of mild or moderate severity. inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolised bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note: 1. typhoid and paratyphoid infections and infections due to multi-resistant staphylococcus aureus are excluded from the above due to insufficient data. 2. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae.

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride 500 mg - ciprofloxacin tablets usp are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter diversus , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or enterococcus faecalis . acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus . chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or p

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride 500 mg - ciprofloxacin tablets usp are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter diversus , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or enterococcus faecalis . acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus . chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or p

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 250 mg - ciprofloxacin tablets, usp are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, serratia marcescens, proteus mirabilis, providencia rettgeri, morganella morganii, citrobacter diversus, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or enterococcus faecalis. acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus. chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis. lower respiratory tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or penicillin-sus